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Abstract
The PROWESS (Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1%
absolute decrease in mortality with a p value of 0.005. Despite the
impressive results of this trial, criticism of the study has targeted
various aspects of design, analysis and interpretation. Additional
studies of recombinant activated protein C (rhAPC) have added to
our understanding about this drug and to controversy as well. So
how do we deal with rhAPC use in our clinical practice?
The PROWESS (Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis) trial demonstrated a
6.1% absolute decrease in mortality with a p value of 0.005
[1]. Recombinant activated protein C (rhAPC) was approved
by the FDA for use in patients with ‘sepsis induced organ
dysfunction associated with a high risk of death, such as an
APACHE [Acute Physiology and Chronic Health Evaluation] II
of ≥25’. APACHE II ≥25 was used as one marker of high risk
of death because a subset data analysis demonstrated that
the treatment benefit in the PROWESS trial was
predominantly in this group of patients. The European
regulatory body approved rhAPC for multiple organ failure
(again based on subset data analysis from the PROWESS
trial demonstrating increased treatment effect as the number
of organ failures increased). The Surviving Sepsis Campaign
(SSC) Guidelines for the Management of Severe Sepsis and
Septic Shock recommend the use of rhAPC in patients with
high risk of death due to sepsis-induced organ dysfunction
[2]. Since the publication of the SSC guidelines additional
large clinical trials of rhAPC have concluded: the ENHANCE
(Extended Evaluation of Recombinant Human Activated
Protein C), ADDRESS (Administration of Drotrecogin Alfa
(Activated) in Early Stage Severe Sepsis) and pediatric trials
[3-5]. The ENHANCE trial provided supportive evidence for
the favorable benefit/risk ratio observed in the PROWESS
trial and suggested that earlier therapy was more effective
[3]. The ENHANCE trial also revealed a somewhat greater
incidence of serious hemorrhage with rhAPC than was
evident in the PROWESS trial. The results of the ADDRESS
trial, designed with the purpose of prospectively studying the
effect of rhAPC in patients with severe sepsis at low risk of
death, supported the FDA labeling that rhAPC was not of
utility in such patients [4]. However, a post hoc subset
analysis of patients who were admitted to a trial designed to
target a low risk of death but who also had an APACHE II
≥25 failed to show benefit in this group. The pediatric trial
failed to show efficacy [5].
The FDA labeling recommends use in patients with sepsis-
induced organ dysfunction and at high risk of death but only
goes as far as identifying patients with APACHE II ≥25 as an
example of such a group. Patients at high risk of death from
severe sepsis would indeed seem the appropriate target
group for rhAPC. But how are these patients identified? The
SSC recommendation lists four groups of patients that satisfy
high risk of death: acute respiratory distress syndrome, septic
shock, multiple organ failure and APACHE II ≥25.
So which adult patients should be targeted for rhAPC
therapy? The key seems to be in the clinical assessment of
risk of death. PROWESS enrolled patients with single and
multiple organ failure, APACHE II ≥25 and APACHE II <25,
and enrolled patients who could have been classified a priori
as having either high or low clinical assessment of risk of
death. Unfortunately we do not know what the assessments
of risk of death were because clinicians treating the patient
were not required to make that assessment and it was not
part of the data collection. The FDA then recommended the
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use of rhAPC in patients at high risk of death and required a
repeat trial in patients at low risk of death. The specified
intent of the ADDRESS trial was to enroll patients at low risk
of death, which would typically be those with single organ
failure and lower APACHE II, whereas the PROWESS study
had patients that clinicians could have clinically assessed as
being at high risk of death and others at low risk of death.
Perhaps if there had been an a priori assignment of clinical
assessment of risk of death in the PROWESS trial, the effect
of rhAPC in these patients would have been enhanced. So
the key to patient selection for administration of rhAPC might
be a priori assessment of risk of death. Septic shock, acute
respiratory distress syndrome (ARDS) and multiple organ
failure are typically those states that would make a clinician
clinically assess a patient as high risk of death. Or should we
garner direction by looking at subgroup analyses of the
PROWESS trial as to which patient groups appeared to
benefit (septic shock, APACHE II ≥25, multiple organ failure
and thrombocytopenia). How does one balance or blend
clinical assessment of high risk of death (PROWESS minus
ADDRESS patient populations) against subset analyses from
PROWESS. Not an easy answer here.
Is APACHE II ≥25 alone, regardless of risk of death assess-
ment, a valid criterion for patient selection? This issue has
been raised by the ADDRESS trial results; however, it must
be remembered that this analysis in the ADDRESS trial was a
post hoc subset analysis. This type of analysis is problematic.
If the ADDRESS trial was the only randomized prospective
trial so far performed and the only group that showed benefit
in that trial was the APACHE II ≥25 subgroup (as a post hoc
subset analysis), no one would be arguing that it should be
used in that group. It is even more interesting when we
recognize that the advocates of this line of thinking are now
using a post hoc subset analysis from one trial to refute a
post hoc subset analysis from another trial! So perhaps the
APACHE II was never appropriate for patient identification
from the start.
Which is more important in identifying risk of death
prospectively: a clinical assessment of risk of death or
APACHE II scoring? The PROWESS trial had no inclusion
criteria related to clinical assessment of risk of death. In that
trial there was a 44% mortality rate in placebo patients with
APACHE II ≥25 whereas in the ADDRESS trial, which
targeted the enrollment of patients with a clinical assessment
of a low risk of death, the mortality was 25% in the APACHE
II  ≥25 group [4,6]. This suggests that the key is clinical
assessment of death and not APACHE II score.
Finally, one additional subset analysis deserves mentioning. In
the ADDRESS trial, patients with recent surgery and single
organ dysfunction who received rhAPC had significantly
higher 28-day mortality rates (20.7% versus 14.1%, p = 0.03,
n = 635) [4]. Should this ADDRESS post hoc subset analysis
also influence our prescribing of rhAPC as being different in
surgery patients? If this had been the only subgroup that was
different in the ADDRESS trial but the post-hoc subset
analysis had shown benefit instead of harm, would we be
recommending that it be used in this group? If we let this
influence our practice, should it be only for post-operative
patients with clinical assessment of low risk of death and
single organ failure?
In my opinion the decision on administration of rhAPC should
be based on a seasoned clinician’s clinical assessment of
high risk of death from sepsis-induced organ failure and
acceptable risk of bleeding complications. Typically high risk
of death will be associated with septic shock, ARDS or
multiple organ failure.
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